Combidex clearly marks out malignant lymph nodes
This article was originally published in Clinica
Executive Summary
An investigational MRI contrast agent that more accurately identifies metastatic lymph node disease in prostate cancer patients could enable doctors to make more appropriate treatment decisions, says a US research team.